uniQure has reported four-year follow-up data for ifezuntirgene inilparvovec, formerly known as AMT-130, showing continued slowing of functional decline in patients with Huntington’s disease after a single administration of the investigational gene therapy. Among 12 high-dose patients evaluated at 48 months, Total Functional Capacity declined 61% more slowly than in a propensity-matched external control, while the composite Unified Huntington’s Disease Rating Scale showed a 44% slowing of progression that did not reach statistical significance. The findings extend the duration of observed treatment effect beyond the three-year dataset already used to support uniQure’s submitted U.S. Biologics License Application.
The update is encouraging but requires careful interpretation because the studies remain small and rely heavily on external natural-history controls rather than a long-term randomized untreated comparison group. Missing data in the updated ENROLL-HD control population also reached 53% at four years, creating uncertainty around the magnitude of the apparent treatment effect. uniQure argues that the missingness likely makes the treatment benefit look smaller rather than larger, but that explanation remains part of the company’s interpretation and will ultimately need to be assessed by regulators.
Four-year results show continued functional separation despite a weaker cUHDRS comparison
The 48-month analysis included 12 patients treated with the high dose of ifezuntirgene inilparvovec and 12 treated with the lower dose. Outcomes were compared with patients drawn from the ENROLL-HD natural-history database using propensity-score matching intended to create a clinically similar untreated comparator population.
For the high-dose group, mean change from baseline on the composite Unified Huntington’s Disease Rating Scale was -0.90 compared with -1.61 for the updated external control. That translated into an estimated 44% slowing of progression, but the comparison produced a p-value of 0.144 and therefore did not meet conventional statistical significance.
Total Functional Capacity produced a stronger result. High-dose patients declined by an average of 0.37 points from baseline compared with a 0.94-point decline in the matched external control, corresponding to a 61% slowing of deterioration with a nominal p-value of 0.008.
Total Functional Capacity is particularly relevant in Huntington’s disease because it reflects patients’ ability to maintain everyday independence, including employment, household responsibilities and self-care. Preserving function over several years would therefore represent a meaningful clinical outcome if the effect is confirmed.
The four-year results also continued to show separation between the high- and low-dose groups. Mean cUHDRS change was -0.91 in high-dose patients compared with -1.94 in the low-dose group, while mean Total Functional Capacity change was -0.30 versus -0.70. uniQure said the pattern was consistent with a dose-dependent treatment effect, although the studies were not powered as definitive head-to-head dose comparisons.
Expanded three-year dataset strengthens the evidence underlying the submitted BLA
The most statistically persuasive part of the new update came from the expanded 36-month analysis. Three additional high-dose patients had reached three years of follow-up since the previous analysis, increasing the high-dose dataset at that time point to 15 patients.
In those 15 patients, cUHDRS declined by an average of 0.28 points compared with a 1.39-point decline in the external control, representing an estimated 80% slowing of disease progression and a nominal p-value of 0.005. Total Functional Capacity declined by 0.27 points compared with 0.82 points in the control population, corresponding to a 67% slowing with a nominal p-value of 0.011.
Those findings are directly relevant to uniQure’s regulatory strategy because the FDA previously told the company that three-year data from 12 high-dose patients could serve as the primary basis for a BLA under the accelerated approval pathway. uniQure subsequently submitted the application using that earlier dataset, meaning the newly reported results were not included in the original filing.
The expanded 15-patient analysis therefore provides additional supportive evidence around the same regulatory time point rather than changing the fundamental dataset on which the BLA was initially built. Whether regulators ultimately view the external-control methodology and magnitude of benefit as sufficient for accelerated approval remains one of the central questions surrounding the program.
External-control missingness complicates interpretation of the four-year treatment effect
The biggest methodological issue in the new dataset involves the updated ENROLL-HD comparator. uniQure reported that missing observations increased as follow-up lengthened, reaching approximately 53% at the 48-month time point. According to the company, patients who stopped contributing follow-up data to the natural-history dataset had been progressing faster than those who remained. If faster-progressing patients disproportionately disappear from the external control, the remaining control population may appear healthier and decline more slowly than the true untreated Huntington’s disease population.
uniQure argues that this survivor effect likely reduced the apparent difference between treated patients and the external control at four years. The company therefore conducted a post hoc sensitivity analysis using the earlier version of the ENROLL-HD comparator, which showed a 53.5% slowing on cUHDRS and a 68.3% slowing on Total Functional Capacity. Those analyses produced nominal p-values of 0.041 and 0.001, respectively.
The sensitivity analysis supports uniQure’s interpretation, but it does not eliminate the uncertainty introduced by changing external controls. Post hoc analyses are inherently less robust than prespecified comparisons, and regulators will need to determine whether the natural-history methodology provides a sufficiently reliable estimate of what would have happened without treatment.
That distinction is particularly important because the primary 48-month cUHDRS comparison did not reach statistical significance using the updated control. The four-year data therefore support continued biological and functional activity, but they should not be presented as an unqualified statistically positive result.
Ifezuntirgene aims to silence mutant huntingtin after a single neurosurgical administration
Ifezuntirgene inilparvovec is designed as a one-time gene therapy targeting the underlying biology of Huntington’s disease. It uses uniQure’s miQURE platform to deliver a microRNA intended to reduce production of huntingtin protein, including the toxic exon 1 fragment believed to contribute to neuronal degeneration.
Treatment is delivered directly into the striatum through MRI-guided stereotactic neurosurgery using convection-enhanced administration. That invasive approach differs markedly from oral or infused medicines but is intended to provide durable expression after a single treatment.
Huntington’s disease is caused by an expanded CAG repeat in the HTT gene and produces progressively worsening motor, cognitive and psychiatric symptoms. Approximately 75,000 people in the United States, European Union and United Kingdom are estimated to have the disease, and there is currently no approved therapy proven to slow its underlying progression.
That unmet need explains why even relatively small early datasets have drawn substantial attention. A therapy capable of meaningfully slowing functional deterioration for several years after one administration would represent a major shift from existing medicines that primarily address symptoms.
Safety remains manageable but CNS inflammation continues to warrant monitoring
uniQure said ifezuntirgene continued to be generally well tolerated across both dose groups. The most common adverse events were related to the neurosurgical administration procedure, and those events had resolved.
Five high-dose participants, representing 17% of that treatment population across the broader program, experienced treatment-related serious adverse events involving central nervous system inflammation. All of those events fully resolved, but the finding remains clinically important because inflammatory complications could influence patient selection, monitoring requirements and the overall risk-benefit assessment of a one-time intracranial gene therapy.
Cerebrospinal fluid neurofilament light protein, a marker associated with neuronal injury, was 6% below baseline among evaluable high-dose patients at 36 months and 4% above baseline at 48 months. The small sample sizes make those biomarker changes difficult to interpret independently, but continued monitoring may help clarify longer-term neurological effects.
Regulatory review now becomes the decisive test for uniQure’s Huntington’s disease strategy
Ifezuntirgene has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA. uniQure has already submitted its BLA in the United States and a separate marketing application in the United Kingdom, positioning the program as the most advanced potential disease-modifying gene therapy for Huntington’s disease.
The FDA filing relies primarily on the three-year high-dose analysis, while a confirmatory study is expected to use Total Functional Capacity as a key measure. That makes the continued TFC separation at four years particularly relevant, even though the cUHDRS result at the same time point was statistically weaker.
The regulatory debate is likely to center on whether the magnitude and durability of benefit outweigh the uncertainty created by small patient numbers, external comparators and an invasive delivery procedure. Accelerated approval can allow earlier access when serious diseases lack effective treatments, but regulators still need evidence that the observed clinical effect is sufficiently persuasive and that confirmatory testing can verify benefit after approval.
The latest results strengthen the durability narrative around ifezuntirgene without resolving those questions. High-dose patients continued to show slower functional deterioration after four years, and the expanded three-year dataset produced larger and statistically stronger differences than the earlier analysis. At the same time, the non-significant four-year cUHDRS result and substantial missingness in the updated external control underline why the program remains scientifically and regulatorily complex.
If FDA reviewers accept the three-year dataset and external-control methodology, ifezuntirgene could become the first approved treatment intended to slow Huntington’s disease progression rather than simply manage symptoms. The four-year update provides additional evidence that the treatment effect may persist, but regulatory review will determine whether that evidence is strong enough to support the gene therapy’s benefit-risk case.
